Paramyxoviridae Infections is an indication for drug development with over 250 pipeline drugs currently active. According to GlobalData, preregistered drugs for Paramyxoviridae Infections have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Paramyxoviridae Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Paramyxoviridae Infections overview

The Paramyxoviridae family belongs to the order Mononegavirales, the distinctive feature of which is a negative-stranded RNA genome and a similar strategy of replication, known to cause different types of infections in vertebrates. Examples of these infections in humans include the measles virus, mumps virus, parainfluenza virus, and respiratory syncytial virus (RSV). The majority of paramyxoviruses are respiratory pathogens and transmission occurs via aerosols or direct contact with infectious secretions, or in some cases, by fecal-oral contact. Paramyxoviridae contain two subfamilies: Paramyxovirinae and Pneumovirinae. The Paramyxovirinae subfamily contains five genera: Respirovirus (human parainfluenza virus 3, Sendai), Rubulavirus (Mumps, human parainfluenza virus 5), Avulavirus (Avian parainfluenza, Newcastle disease), Morbillivirus (Measles, canine distemper), and Henipavirus. Clinical features of HPIV infection include both upper and lower respiratory tract illneses. Children present with fever, croup, laryngeal obstruction, and inspiratory stridor. The virus can also cause bonchiolitis in infants, pneumonia in children, tracheobronchitis, and giant-cell pneumonia in immunocompromised individuals. It has been associated with neurologic disease including seizures, encephalitis, and demyelinating syndromes, suggesting that the virus can be neurotropic.

For a complete picture of PTSR and LoA scores for drugs in Paramyxoviridae Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.